Cargando…

Integrated Network Pharmacology Analysis and Pharmacological Evaluation to Explore the Active Components and Mechanism of Abelmoschus manihot (L.) Medik. on Renal Fibrosis

BACKGROUND: Renal fibrosis is a common pathological outcome of chronic kidney diseases (CKD) that is considered as a global public health issue with high morbidity and mortality. The dry corolla of Abelmoschus manihot (L.) Medik. (AMC) has been used for chronic nephritis in clinic and showed a super...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Lifei, Hong, Fang, Fan, Kaikai, Zhao, Lei, Zhang, Chunlei, Yu, Boyang, Chai, Chengzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7535141/
https://www.ncbi.nlm.nih.gov/pubmed/33061308
http://dx.doi.org/10.2147/DDDT.S264898
_version_ 1783590422424059904
author Gu, Lifei
Hong, Fang
Fan, Kaikai
Zhao, Lei
Zhang, Chunlei
Yu, Boyang
Chai, Chengzhi
author_facet Gu, Lifei
Hong, Fang
Fan, Kaikai
Zhao, Lei
Zhang, Chunlei
Yu, Boyang
Chai, Chengzhi
author_sort Gu, Lifei
collection PubMed
description BACKGROUND: Renal fibrosis is a common pathological outcome of chronic kidney diseases (CKD) that is considered as a global public health issue with high morbidity and mortality. The dry corolla of Abelmoschus manihot (L.) Medik. (AMC) has been used for chronic nephritis in clinic and showed a superior effect in alleviating proteinuria in CKD patients to losartan. However, the effective components and underlying mechanism of AMC in the treatment of renal fibrosis have not been systematically clarified. METHODS: Based on drug-likeness evaluation, oral bioavailability prediction and compound contents, a systematic network pharmacology analysis was conducted to predict the active ingredients. Gene Ontology, Kyoto Encyclopedia of Genes and Genomes pathway analysis and protein–protein interaction analysis were applied to predict the potential pathway and target of AMC against renal fibrosis. The formula of component contribution index (CI) based on the algorithm was used to screen the principal active compounds of AMC in the treatment of renal fibrosis. Finally, pharmacological evaluation was conducted to validate the protective effect and primary predicted mechanism of AMC in the treatment of renal fibrosis on a 5/6 nephrectomy mice model. RESULTS: Fourteen potential active components of AMC possessing favorable pharmacokinetic profiles and biological activities were selected and hit by 17 targets closely related to renal fibrosis. Quercetin, caffeic acid, 9.12-octadecadienoic acid, and myricetin are recognized as the more highly predictive components as their cumulative contribution rate reached 85.86%. The AMC administration on 5/6 nephrectomy mice showed a protective effect on kidney function and renal fibrosis. The hub genes analysis revealed that AMC plays a major role in inhibiting epithelial-to-mesenchymal transition during renal fibrosis. CONCLUSION: Our results predicted active components and potential targets of AMC for the application to renal fibrosis from a holistic perspective, as well as provided valuable direction for further research of AMC and improved comprehension of renal fibrosis pathogenesis.
format Online
Article
Text
id pubmed-7535141
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-75351412020-10-14 Integrated Network Pharmacology Analysis and Pharmacological Evaluation to Explore the Active Components and Mechanism of Abelmoschus manihot (L.) Medik. on Renal Fibrosis Gu, Lifei Hong, Fang Fan, Kaikai Zhao, Lei Zhang, Chunlei Yu, Boyang Chai, Chengzhi Drug Des Devel Ther Original Research BACKGROUND: Renal fibrosis is a common pathological outcome of chronic kidney diseases (CKD) that is considered as a global public health issue with high morbidity and mortality. The dry corolla of Abelmoschus manihot (L.) Medik. (AMC) has been used for chronic nephritis in clinic and showed a superior effect in alleviating proteinuria in CKD patients to losartan. However, the effective components and underlying mechanism of AMC in the treatment of renal fibrosis have not been systematically clarified. METHODS: Based on drug-likeness evaluation, oral bioavailability prediction and compound contents, a systematic network pharmacology analysis was conducted to predict the active ingredients. Gene Ontology, Kyoto Encyclopedia of Genes and Genomes pathway analysis and protein–protein interaction analysis were applied to predict the potential pathway and target of AMC against renal fibrosis. The formula of component contribution index (CI) based on the algorithm was used to screen the principal active compounds of AMC in the treatment of renal fibrosis. Finally, pharmacological evaluation was conducted to validate the protective effect and primary predicted mechanism of AMC in the treatment of renal fibrosis on a 5/6 nephrectomy mice model. RESULTS: Fourteen potential active components of AMC possessing favorable pharmacokinetic profiles and biological activities were selected and hit by 17 targets closely related to renal fibrosis. Quercetin, caffeic acid, 9.12-octadecadienoic acid, and myricetin are recognized as the more highly predictive components as their cumulative contribution rate reached 85.86%. The AMC administration on 5/6 nephrectomy mice showed a protective effect on kidney function and renal fibrosis. The hub genes analysis revealed that AMC plays a major role in inhibiting epithelial-to-mesenchymal transition during renal fibrosis. CONCLUSION: Our results predicted active components and potential targets of AMC for the application to renal fibrosis from a holistic perspective, as well as provided valuable direction for further research of AMC and improved comprehension of renal fibrosis pathogenesis. Dove 2020-10-01 /pmc/articles/PMC7535141/ /pubmed/33061308 http://dx.doi.org/10.2147/DDDT.S264898 Text en © 2020 Gu et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Gu, Lifei
Hong, Fang
Fan, Kaikai
Zhao, Lei
Zhang, Chunlei
Yu, Boyang
Chai, Chengzhi
Integrated Network Pharmacology Analysis and Pharmacological Evaluation to Explore the Active Components and Mechanism of Abelmoschus manihot (L.) Medik. on Renal Fibrosis
title Integrated Network Pharmacology Analysis and Pharmacological Evaluation to Explore the Active Components and Mechanism of Abelmoschus manihot (L.) Medik. on Renal Fibrosis
title_full Integrated Network Pharmacology Analysis and Pharmacological Evaluation to Explore the Active Components and Mechanism of Abelmoschus manihot (L.) Medik. on Renal Fibrosis
title_fullStr Integrated Network Pharmacology Analysis and Pharmacological Evaluation to Explore the Active Components and Mechanism of Abelmoschus manihot (L.) Medik. on Renal Fibrosis
title_full_unstemmed Integrated Network Pharmacology Analysis and Pharmacological Evaluation to Explore the Active Components and Mechanism of Abelmoschus manihot (L.) Medik. on Renal Fibrosis
title_short Integrated Network Pharmacology Analysis and Pharmacological Evaluation to Explore the Active Components and Mechanism of Abelmoschus manihot (L.) Medik. on Renal Fibrosis
title_sort integrated network pharmacology analysis and pharmacological evaluation to explore the active components and mechanism of abelmoschus manihot (l.) medik. on renal fibrosis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7535141/
https://www.ncbi.nlm.nih.gov/pubmed/33061308
http://dx.doi.org/10.2147/DDDT.S264898
work_keys_str_mv AT gulifei integratednetworkpharmacologyanalysisandpharmacologicalevaluationtoexploretheactivecomponentsandmechanismofabelmoschusmanihotlmedikonrenalfibrosis
AT hongfang integratednetworkpharmacologyanalysisandpharmacologicalevaluationtoexploretheactivecomponentsandmechanismofabelmoschusmanihotlmedikonrenalfibrosis
AT fankaikai integratednetworkpharmacologyanalysisandpharmacologicalevaluationtoexploretheactivecomponentsandmechanismofabelmoschusmanihotlmedikonrenalfibrosis
AT zhaolei integratednetworkpharmacologyanalysisandpharmacologicalevaluationtoexploretheactivecomponentsandmechanismofabelmoschusmanihotlmedikonrenalfibrosis
AT zhangchunlei integratednetworkpharmacologyanalysisandpharmacologicalevaluationtoexploretheactivecomponentsandmechanismofabelmoschusmanihotlmedikonrenalfibrosis
AT yuboyang integratednetworkpharmacologyanalysisandpharmacologicalevaluationtoexploretheactivecomponentsandmechanismofabelmoschusmanihotlmedikonrenalfibrosis
AT chaichengzhi integratednetworkpharmacologyanalysisandpharmacologicalevaluationtoexploretheactivecomponentsandmechanismofabelmoschusmanihotlmedikonrenalfibrosis